Dr. Tung Wynn, MD
Claim this profileUniversity of Florida Hemophilia Treatment Center
Studies Von Willebrand Disease
Studies Hemophilia
6 reported clinical trials
10 drugs studied
Area of expertise
1Von Willebrand Disease
2Hemophilia
FVIII Level positive
FVIII Gene Mutation positive
Affiliated Hospitals
Clinical Trials Tung Wynn, MD is currently running
Natural History Study
for Blood Disorders
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well-controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.(1,2,3,4) In 2019 alone, the United States Food and Drug Administration (FDA) has issued approvals for twenty-four new therapies for congenital and acquired hematologic conditions.(5) In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.(6) With this increase in potential new therapies on the horizon, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data. ATHN Transcends is a cohort study to determine the safety, effectiveness, and practice of therapies used in the treatment of participants with congenital or acquired non-neoplastic blood disorders and connective tissue disorders with bleeding tendency. The study consists of 7 cohorts with additional study "arms" and "modules" branching off from the cohorts. The overarching objective of this longitudinal, observational study is to characterize the safety, effectiveness and practice of treatments for all people with congenital and acquired hematologic disorders in the US. As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.(7)
Recruiting1 award N/A1 criteria
rVWF +/− ADVATE
for Von Willebrand Disease
The main aim of the study is to check effectiveness, side effects, and tolerability of vonicog alfa (recombinant von Willebrand factor \[rVWF\]), with or without ADVATE, in the treatment and control of nonsurgical bleeding events in pediatric participants (less than (\<)18 years of age) with severe hereditary von Willebrand disease (VWD). The participants will be treated with vonicog alfa for 12-18 months. Their von Willebrand Disease will be treated by their doctor according to their doctor's usual clinical practice. During the study, participants will be followed up at clinics or over telephone calls.
Recruiting2 awards Phase 3
More about Tung Wynn, MD
Clinical Trial Related5 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Tung Wynn, MD has experience with
- Various VWF Regimens
- Antihemophilic Factor (Recombinant)
- Von Willebrand Factor (Recombinant)
- ATHN Transcends
- ITI
- PEGylated Recombinant Factor VIII
Breakdown of trials Tung Wynn, MD has run
Von Willebrand Disease
Hemophilia
Hemophilia A
Thalassemia
Sickle Cell Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tung Wynn, MD specialize in?
Tung Wynn, MD focuses on Von Willebrand Disease and Hemophilia. In particular, much of their work with Von Willebrand Disease has involved treating patients, or patients who are undergoing treatment.
Is Tung Wynn, MD currently recruiting for clinical trials?
Yes, Tung Wynn, MD is currently recruiting for 2 clinical trials in Gainesville Florida. If you're interested in participating, you should apply.
Are there any treatments that Tung Wynn, MD has studied deeply?
Yes, Tung Wynn, MD has studied treatments such as Various VWF Regimens, Antihemophilic Factor (Recombinant), von Willebrand factor (Recombinant).
What is the best way to schedule an appointment with Tung Wynn, MD?
Apply for one of the trials that Tung Wynn, MD is conducting.
What is the office address of Tung Wynn, MD?
The office of Tung Wynn, MD is located at: University of Florida Hemophilia Treatment Center, Gainesville, Florida 32610 United States. This is the address for their practice at the University of Florida Hemophilia Treatment Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.